당뇨병성 망막증 시장, 점유율, 시장 규모, 동향, 산업 분석 보고서 : 유형별, 관리 방법별, 지역별, 부문별 동향(2023-2032년)

The global diabetic retinopathy market size is expected to reach USD 15.23 billion by 2032, according to a new study by Polaris Market Research. The report "Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence of diabetes has been witnessing a significant surge, with a substantial impact on global health. According to the International Diabetes Federation, the number of individuals affected by diabetes was approximately 537 million in 2021. This figure is projected to increase to 643 million by 2030 and a staggering 783 million by 2045. Diabetes is recognized as one of the leading causes of blindness worldwide.

Blindness in individuals with diabetes is often attributed to the damage caused by leaking or ruptured blood vessels in the retina. The severity of vision loss can vary, ranging from permanent impairment to temporary disruptions depending on the stage of the disease. Research indicates that the number of cases of diabetic retinopathy, a specific form of vision impairment associated with diabetes, was estimated to be around 103.12 million in 2020. It is anticipated that the number of cases will escalate to approximately 160.5 million by 2045.

The aging population presents unique challenges in terms of healthcare needs, including a higher prevalence of chronic diseases like diabetes. With advancements in medical care and improved life expectancy, the number of individuals aged 65 years and over is projected to escalate substantially. For instance, the "Aging in the United States" report by the Population Reference Bureau indicates that the population of individuals aged 65 years and above in the U.S. is estimated to grow from approximately 46 million in 2016 to over 98 million by the year 2060.

This demographic shift underscores the importance of addressing health issues associated with aging, including diabetic retinopathy. Healthcare providers and manufacturers in the market must be prepared to meet the growing demands of this expanding population and provide effective solutions to manage diabetic retinopathy and preserve vision in older adults.

The COVID-19 pandemic had a substantial impact on healthcare systems worldwide, including the diagnosis and treatment of diabetic retinopathy. Due to the constraints and restrictions imposed during the pandemic, early detection and treatment guidelines for diabetic retinopathy were significantly affected. Intravitreal injections, which are a common treatment modality for diabetic retinopathy, experienced a significant decrease in usage globally during the pandemic compared to 2019. Reduction percentages varied but ranged from approximately 30% to over 100%.

Diabetic Retinopathy Market Report Highlights

Non-proliferative diabetic retinopathy segment accounted for highest global market share in 2022, due to rise in number of cases of diabetes

Anti-VEGF segment accounted largest share, due its high efficacy and better treatment algorithm

Asia Pacific region grown at the fastest rate, owing huge un-tapped population and better patient awareness

The global key market players include: Bayer, Allergan, Novartis, Oxurion, Sirnaomics, Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, and Kowa Company.

Polaris Market Research has segmented the diabetic retinopathy market report based on type, management, and region:

Diabetic Retinopathy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Proliferative Diabetic Retinopathy
• Non-proliferative diabetic retinopathy

Diabetic Retinopathy, Management Outlook (Revenue - USD Billion, 2019 - 2032)

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy

Diabetic Retinopathy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Diabetic Retinopathy Market Insights

• 4.1. Diabetic Retinopathy Market - Industry Snapshot
• 4.2. Diabetic Retinopathy Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising prevalence of diabetes and increasing prevalence of blindness due to diabetes
    • 4.2.1.2. Growing awareness about diabetes care and management and new product launches
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High cost
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Diabetic Retinopathy Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Diabetic Retinopathy Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Diabetic Retinopathy, by Type, 2019-2032 (USD Billion)
• 5.3. Proliferating Diabetic retinopathy
  • 5.3.1. Global Diabetic Retinopathy Market, by Proliferating Diabetic retinopathy, by Region, 2019-2032 (USD Billion)
• 5.4. Non proliferating Diabetic Retinopathy
  • 5.4.1. Global Diabetic Retinopathy Market, by Non proliferating Diabetic Retinopathy, by Region, 2019-2032 (USD Billion)

6. Global Diabetic Retinopathy Market, by Management

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
• 6.3. Anti VEGF
  • 6.3.1. Global Diabetic Retinopathy Market, by Anti VEGF, by Region, 2019-2032 (USD Billion)
• 6.4. Intraocular Steroid Injection
  • 6.4.1. Global Diabetic Retinopathy Market, by Intraocular Steroid Injection, by Region, 2019-2032 (USD Billion)
• 6.4. Laser Surgery
  • 6.4.1. Global Diabetic Retinopathy Market, by Laser Surgery, by Region, 2019-2032 (USD Billion)
• 6.5. Vitrectomy
  • 6.5.1. Global Diabetic Retinopathy Market, by Vitrectomy, by Region, 2019-2032 (USD Billion)

7. Global Diabetic Retinopathy Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Diabetic Retinopathy Market Assessment, By Geography, 2019-2032 (USD Billion)
• 7.3. Diabetic Retinopathy Market - North America
  • 7.3.1. North America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 7.3.2. North America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.3.3. Diabetic Retinopathy Market - U.S.
    • 7.3.3.1. U.S.: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.3.3.2. U.S.: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.3.4. Diabetic Retinopathy Market - Canada
    • 7.3.4.1. Canada: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.3.4.2. Canada: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
• 7.4. Diabetic Retinopathy Market - Europe
  • 7.4.1. Europe: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 7.4.2. Europe: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.3. Diabetic Retinopathy Market - UK
    • 7.4.3.1. UK: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.3.2. UK: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.4. Diabetic Retinopathy Market - France
    • 7.4.4.1. France: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.4.2. France: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.5. Diabetic Retinopathy Market - Germany
    • 7.4.5.1. Germany: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.5.2. Germany: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.6. Diabetic Retinopathy Market - Italy
    • 7.4.6.1. Italy: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.6.2. Italy: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.7. Diabetic Retinopathy Market - Spain
    • 7.4.7.1. Spain: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.7.2. Spain: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.8. Diabetic Retinopathy Market - Netherlands
    • 7.4.8.1. Netherlands: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.8.2. Netherlands: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4.9. Diabetic Retinopathy Market - Russia
    • 7.4.9.1. Russia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.9.2. Russia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
• 7.5. Diabetic Retinopathy Market - Asia Pacific
  • 7.5.1. Asia Pacific: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 7.5.2. Asia Pacific: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.3. Diabetic Retinopathy Market - China
    • 7.5.3.1. China: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.3.2. China: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.4. Diabetic Retinopathy Market - India
    • 7.5.4.1. India: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.4.2. India: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.5. Diabetic Retinopathy Market - Malaysia
    • 7.5.5.1. Malaysia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.5.2. Malaysia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.6. Diabetic Retinopathy Market - Japan
    • 7.5.6.1. Japan: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.6.2. Japan: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.7. Diabetic Retinopathy Market - Indonesia
    • 7.5.7.1. Indonesia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.7.2. Indonesia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5.8. Diabetic Retinopathy Market - South Korea
    • 7.5.8.1. South Korea: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.8.2. South Korea: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
• 7.6. Diabetic Retinopathy Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 7.6.2. Middle East & Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.6.3. Diabetic Retinopathy Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.6.4. Diabetic Retinopathy Market - UAE
    • 7.6.4.1. UAE: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.6.4.2. UAE: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.6.5. Diabetic Retinopathy Market - Israel
    • 7.6.5.1. Israel: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.6.5.2. Israel: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.6.6. Diabetic Retinopathy Market - South Africa
    • 7.6.6.1. South Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.6.6.2. South Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
• 7.7. Diabetic Retinopathy Market - Latin America
  • 7.7.1. Latin America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 7.7.2. Latin America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.7.3. Diabetic Retinopathy Market - Mexico
    • 7.7.3.1. Mexico: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.7.3.2. Mexico: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.7.4. Diabetic Retinopathy Market - Brazil
    • 7.7.4.1. Brazil: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.7.4.2. Brazil: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.7.5. Diabetic Retinopathy Market - Argentina
    • 7.7.5.1. Argentina: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.7.5.2. Argentina: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. Bayer
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Allergan
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Novartis
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Oxurion
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Sirnaomics
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Genentech
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. Alimera Sciences
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Ampio Pharmaceuticals
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. BCN Peptides
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Kowa Company
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development